Kenya can clear a device registration in 48 hours

One set of Rules, sorted by risk first

The Pharmacy and Poisons (Registration of Health Products and Technologies) Rules, 2022, made under the Pharmacy and Poisons Act (Cap. 244), give Kenya's PPB a four-class risk ladder for medical devices — A through D, low to high — the same broad shape as the harmonized classification several other markets this blog has covered already run against. Class A, the lowest-risk tier, clears through listing rather than a full evaluation. Everything above it goes through a substantive review, submitted through the Board's own online portal — but “substantive review” isn't one process. For Class B and above, PPB names several distinct evaluation routes off the same set of Rules, and which one a filing lands on depends on evidence the sponsor brings in, not on the class alone.

No foreign approval buys the slow lane

A device with no qualifying approval from another regulator goes through PPB's Full Evaluation Route, the only path that asks PPB to build its own judgment from scratch, and it runs accordingly: roughly six to twelve months. That's the baseline every faster route is measured against, and it's the route a sponsor lands on by default if it can't document anything better.

Reference-agency approval buys speed; duration buys more of it

Hold approval from at least two of the reference regulatory authorities PPB recognizes, and a device qualifies for the Abridged Evaluation Route instead, targeted at three to six months. Beyond that, PPB's Rules add a second variable most reference-market shortcuts don't bother with: how long that foreign approval has been in force without an adverse finding attached to it. Expedited Class B Registration asks for either three clean years behind at least two reference-agency approvals, or three reference-agency approvals outright, and runs one to three months. Immediate Class B Registration sits at the top of the ladder: at least three reference-agency approvals and four years of clean market history, reviewed on a target of 48 hours.

Forty-eight hours is a review speed, not a waived review

None of this exempts a device from registration. A sponsor claiming the Immediate route still has to document the specific approvals and the specific clean-history period the claim rests on; the speed is what PPB owes the claim once it's substantiated, not a standing invitation to skip the file. A device with the paperwork to support Expedited or Immediate treatment that's filed instead as a bare Abridged submission, with the stronger evidence never surfaced, has simply chosen a slower queue than its own file could have supported.

Where this meets the file

A Kenya row in a cross-border registration tracker needs the claimed route recorded as its own field, backed by the specific reference-agency approvals and their in-force dates feeding that claim — not a single “fast-tracked: yes/no” box standing in for evidence a reviewer still has to see named. Kenya's own regulatory structure is itself mid-consolidation, with legislation to fold PPB into a single health-products authority moving through Parliament; the routes above are the ones the 2022 Rules run today, and the ones a filing has to clear under until that changes. A registration tracker built around this structure, alongside the launch catalog's other cross-border templates, is previewed there now. If your program has tracked PPB's routes differently, the shelf takes that correction directly.